Literature DB >> 17302732

Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.

N Pelli1, A Floreani, F Torre, A Delfino, A Baragiotta, P Contini, M Basso, A Picciotto.   

Abstract

Apoptosis in the liver is generated mainly by the Fas system. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed recently as a new apoptotic inducer. In the liver environment hepatocytes and biliary epithelial cells express TRAIL receptors which are up-regulated by increased levels of bile acids and during viral hepatitis. As for FasL, a soluble form of TRAIL has been described. To explore the commitment and level of activation of these two apoptotic systems in patients affected by primary biliary cirrhosis (PBC) or chronic hepatitis C (CH-C), a comparative study was drawn. Thirty patients with PBC on ursodeoxycholic acid have been enrolled. This group was compared with 30 patients with CH-C and with 20 healthy subjects. Soluble Fas ligand (sFasL) and soluble TRAIL (sTRAIL) levels were evaluated by double determinant immune assay and enzyme-linked immunosorbent assay (ELISA), respectively. Soluble FasL molecules were higher in PBC compared to CH-C (P=0 x 009). Soluble FasL was not detected in controls. Soluble TRAIL was significantly higher in CH-C patients compared to PBC (P=0 x 0001). Soluble TRAIL levels were higher in PBC and in CH-C than in controls (P=0 x 015 and P<0 x 001, respectively). No correlation between sFasL and sTRAIL, stage of disease, liver histology in each disease and cytolysis was present. Our data show different levels of commitment of TRAIL and Fas apoptosis-inducing systems in CH-C and PBC. Thus a different prominent role of TRAIL and Fas systems in the pathogenesis of these two conditions can be speculated: the former by inducing the death of infected hepatocytes, the latter by mediating the disappearance of bile duct.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302732      PMCID: PMC1868846          DOI: 10.1111/j.1365-2249.2006.03293.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Cell-kinetic study of proliferating bile ductules in various hepatobiliary diseases.

Authors:  K Harada; N Kono; K Tsuneyama; Y Nakanuma
Journal:  Liver       Date:  1998-08

2.  IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.

Authors:  L M Sedger; D M Shows; R A Blanton; J J Peschon; R G Goodwin; D Cosman; S R Wiley
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

3.  Associations of Fas (CD95), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), and biochemical manifestations in elderly persons.

Authors:  Jong Weon Choi
Journal:  Clin Chim Acta       Date:  2005-09-01       Impact factor: 3.786

4.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

5.  Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis.

Authors:  K Harada; S Ozaki; M E Gershwin; Y Nakanuma
Journal:  Hepatology       Date:  1997-12       Impact factor: 17.425

6.  Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults.

Authors:  Jong Weon Choi; Jung Soo Song; Soo Hwan Pai
Journal:  Ann Clin Lab Sci       Date:  2004       Impact factor: 1.256

7.  TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.

Authors:  Chunhai Hao; Jin H Song; Belinda Hsi; Jamie Lewis; Doyoun K Song; Kenneth C Petruk; David L J Tyrrell; Norman M Kneteman
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

8.  Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.

Authors:  W A Faubion; M E Guicciardi; H Miyoshi; S F Bronk; P J Roberts; P A Svingen; S H Kaufmann; G J Gores
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

9.  Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C.

Authors:  Nicoletta Pelli; Francesco Torre; Andrea Delfino; Monica Basso; Antonino Picciotto
Journal:  J Interferon Cytokine Res       Date:  2006-02       Impact factor: 2.607

10.  A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation.

Authors:  C M Rodrigues; G Fan; X Ma; B T Kren; C J Steer
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

View more
  4 in total

1.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

2.  Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis.

Authors:  Yan Liang; Zaixing Yang; Chang Li; Ye Zhu; Lingzhen Zhang; Renqian Zhong
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

3.  Effect of dicycloplatin, a novel platinum chemotherapeutical drug, on inhibiting cell growth and inducing cell apoptosis.

Authors:  Guang-quan Li; Xing-gui Chen; Xing-ping Wu; Jing-dun Xie; Yong-ju Liang; Xiao-qin Zhao; Wei-qiang Chen; Li-wu Fu
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

4.  The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma.

Authors:  Olfat Hammam; Ola Mahmoud; Manal Zahran; Sohair Aly; Karim Hosny; Amira Helmy; Amgad Anas
Journal:  Hepat Mon       Date:  2012-11-03       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.